Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug 17;17(1):191.
doi: 10.1186/s12944-018-0837-y.

Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis

Zhi Luo  1 , Zhan Lu  1 , Irfan Muhammad  1 , Yun Chen  1 , Qiuhong Chen  2 , Jiaojiao Zhang  2 , Yongyan Song  3
Affiliations
Meta-Analysis

Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis

Zhi Luo et al. Lipids Health Dis. .

Abstract

Background: The associations of the 5,10-methylenetetrahydrofolate reductase gene (MTHFR) rs1801133 polymorphism with coronary artery disease (CAD) and plasma lipid levels have been widely investigated, but the results were inconsistent and inconclusive. This meta-analysis aimed to clarify the relationships of the rs1801133 polymorphism with CAD and plasma lipid levels.

Methods: By searching in PubMed, Google Scholar, Web of Science, Cochrane Library, Wanfang, VIP and CNKI databases, 123 studies (87,020 subjects) and 65 studies (85,554 subjects) were identified for the CAD association analysis and the lipid association analysis, respectively. Odds ratio (OR) and standardized mean difference (SMD) were used to determine the effects of the rs1801133 polymorphism on CAD risk and lipid levels, respectively.

Results: The variant T allele of the rs1801133 polymorphism was associated with increased risk of CAD under allelic model [OR = 1.11, 95% confidence interval (CI) = 1.06-1.17, P < 0.01], additive model (OR = 1.25, 95% CI = 1.14-1.37, P < 0.01), dominant model (OR = 1.11, 95% CI = 1.04-1.17, P < 0.01), and recessive model (OR = 1.22, 95% CI = 1.12-1.32, P < 0.01). The T carriers had higher levels of total cholesterol (TC) (SMD = 0.04, 95% CI = 0.01-0.07, P = 0.02) and low-density lipoprotein cholesterol (LDL-C) (SMD = 0.07, 95% CI = 0.01-0.12, P = 0.01) than the non-carriers.

Conclusions: The meta-analysis suggested that the T allele of the rs1801133 polymorphism is a risk factor for CAD, which is possibly and partly mediated by abnormal lipid levels.

Keywords: 5,10-Methylenetetrahydrofolate reductase; Coronary artery disease; Lipid; Polymorphism; rs1801133.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow diagram of the study selection process
Fig. 2
Fig. 2
Forest plot of the meta-analysis between the MTHFR rs1801133 polymorphism and plasma total cholesterol (TC) levels
Fig. 3
Fig. 3
Forest plot of the meta-analysis between the MTHFR rs1801133 polymorphism and plasma low-density lipoprotein cholesterol (LDL-C) levels
Fig. 4
Fig. 4
Forest plot of the meta-analysis between the MTHFR rs1801133 polymorphism and triglycerides (TG) levels
Fig. 5
Fig. 5
Forest plot of the meta-analysis between the MTHFR rs1801133 polymorphism and plasma high-density lipoprotein cholesterol (HDL-C) levels
See this image and copyright information in PMC

References

    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, DK MG, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38–360. doi: 10.1161/CIR.0000000000000350. - DOI - PubMed
    1. Erdmann J, Kessler T, Munoz Venegas L, Schunkert H. A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res. 2018; 10.1093/cvr/cvy084. [Epub ahead of print] - PubMed
    1. O'Donnell FL, Stahlman S, Oetting AA. Incidence rates of diagnoses of cardiovascular diseases and associated risk factors, active component, U.S. Armed Forces, 2007–2016. MSMR. 2018;25:12–18. - PubMed
    1. Wang L, Shangguan S, Chang S, Yu X, Wang Z, Lu X, Wu L, Zhang T. Determining the association between methylenetetrahydrofolate reductase (MTHFR) genepolymorphisms and genomic DNA methylation level: a meta-analysis. Birth Defects Res A Clin Mol Teratol. 2016;106:667–674. doi: 10.1002/bdra.23511. - DOI - PubMed
    1. Xhemalce B. From histones to RNA: role of methylation in cancer. Brief Funct Genomics. 2013;12:244–253. doi: 10.1093/bfgp/els064. - DOI - PubMed

Substances